Your browser is no longer supported. Please, upgrade your browser.
Settings
PTGX Protagonist Therapeutics, Inc. daily Stock Chart
PTGX [NASD]
Protagonist Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.72 Insider Own1.60% Shs Outstand25.75M Perf Week-2.19%
Market Cap356.64M Forward P/E- EPS next Y-2.94 Insider Trans-3.33% Shs Float25.10M Perf Month25.45%
Income-65.90M PEG- EPS next Q-0.71 Inst Own95.60% Short Float3.44% Perf Quarter14.84%
Sales1.80M P/S198.13 EPS this Y16.70% Inst Trans9.66% Short Ratio3.56 Perf Half Y5.24%
Book/sh3.42 P/B4.05 EPS next Y6.70% ROA-46.30% Target Price20.17 Perf Year62.75%
Cash/sh4.90 P/C2.83 EPS next 5Y- ROE-62.50% 52W Range5.49 - 16.67 Perf YTD105.79%
Dividend- P/FCF- EPS past 5Y- ROI-36.90% 52W High-16.92% Beta-
Dividend %- Quick Ratio4.10 Sales past 5Y- Gross Margin- 52W Low152.15% ATR0.89
Employees64 Current Ratio4.10 Sales Q/Q- Oper. Margin- RSI (14)51.64 Volatility5.34% 6.99%
OptionableNo Debt/Eq0.00 EPS Q/Q-189.60% Profit Margin- Rel Volume0.62 Prev Close14.58
ShortableYes LT Debt/Eq0.00 EarningsAug 06 Payout- Avg Volume242.88K Price13.85
Recom1.50 SMA200.61% SMA5011.91% SMA20034.63% Volume150,770 Change-5.01%
Jul-08-19Initiated H.C. Wainwright Buy $23
May-09-19Upgrade Stifel Hold → Buy $11 → $17
Dec-06-18Initiated Nomura Buy $13
Jan-29-18Initiated Stifel Buy $32
Jul-21-17Initiated BTIG Research Buy $36
Sep-04-19 04:30PM  Protagonist Therapeutics Reports Granting of Inducement Awards PR Newswire
Sep-03-19 04:30PM  Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference PR Newswire +9.29%
Aug-27-19 11:51AM  Does Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Salary Reflect Performance? Simply Wall St.
Aug-07-19 08:35AM  Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:00AM  Protagonist Therapeutics Reports Second Quarter 2019 Financial Results PR Newswire
Aug-01-19 04:30PM  Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study PR Newswire
Jul-30-19 10:38AM  Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
Jul-16-19 04:05PM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Jul-11-19 03:36PM  Should You Be Worried About Insider Transactions At Protagonist Therapeutics, Inc. (NASDAQ:PTGX)? Simply Wall St.
Jun-23-19 04:11PM  Heres What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX) Insider Monkey
Jun-18-19 04:30PM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Jun-17-19 07:00AM  Protagonist Therapeutics to Present at the BMO 2019 Prescription for Success Healthcare Conference PR Newswire
Jun-04-19 07:00AM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
May-29-19 04:30PM  Protagonist Therapeutics Appoints Don Kalkofen as Chief Financial Officer PR Newswire
May-15-19 06:23PM  Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript Motley Fool
May-14-19 07:00AM  Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study PR Newswire
May-08-19 08:35AM  Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates Zacks +6.24%
08:00AM  What You Must Know About Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Beta Value Simply Wall St.
07:26AM  Protagonist Therapeutics: 1Q Earnings Snapshot Associated Press
07:01AM  Protagonist Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
07:00AM  Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists PR Newswire
May-07-19 07:00AM  Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019 PR Newswire -11.09%
May-01-19 10:32AM  Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline Zacks
Apr-01-19 07:00AM  Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9 PR Newswire
Mar-18-19 11:12AM  Edited Transcript of PTGX earnings conference call or presentation 12-Mar-19 8:30pm GMT Thomson Reuters StreetEvents +5.73%
Mar-12-19 04:25PM  Protagonist Therapeutics: 4Q Earnings Snapshot Associated Press
04:01PM  Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Mar-05-19 07:00AM  Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results PR Newswire
Feb-21-19 07:00AM  Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28 PR Newswire
Feb-05-19 08:10AM  Investor Expectations to Drive Momentum within Continental Resources, Protagonist Therapeutics, Mobile Mini, J & J Snack Foods, Griffon, and Nordson Discovering Underlying Factors of Influence GlobeNewswire
Jan-16-19 04:30PM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Jan-09-19 07:00AM  Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia PR Newswire
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals
Dec-20-18 10:42AM  Who Has Been Buying Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares? Simply Wall St.
Dec-13-18 07:00AM  Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943 PR Newswire
Dec-05-18 07:00AM  Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference PR Newswire
Nov-29-18 08:09AM  The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga
Nov-27-18 04:01PM  Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease PR Newswire
Nov-09-18 08:40AM  New Research Coverage Highlights American Public Education, Protagonist Therapeutics, TravelCenters of America, Five Prime Therapeutics, Red Robin Gourmet Burgers, and Hemisphere Media Group Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-07-18 04:30PM  Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14 PR Newswire
Nov-06-18 08:05PM  Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates Zacks +9.58%
06:59PM  Protagonist Therapeutics: 3Q Earnings Snapshot Associated Press
04:23PM  Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
07:00AM  Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 PR Newswire
Oct-29-18 10:31AM  Protagonist Therapeutics (PTGX) Q3 Earnings Preview: What to Know Ahead of the Release Zacks
Oct-22-18 08:31AM  Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week PR Newswire -7.05%
Oct-10-18 07:35AM  Report: Developing Opportunities Within Apollo Investment, Ladder Capital, Medpace, MPLX LP, Silicon Laboratories, and Protagonist Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 07:13AM  Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting PR Newswire
Sep-27-18 07:00AM  Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 PR Newswire +15.32%
Sep-24-18 07:00AM  Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 PR Newswire
Sep-19-18 07:00AM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Sep-06-18 07:01AM  Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 PR Newswire
07:00AM  Protagonist Therapeutics Expands Intellectual Property Portfolio PR Newswire
Aug-17-18 04:30PM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
Aug-08-18 11:21AM  Protagonist Stock Jumps 58% After Re-Review of Test Results InvestorPlace
Aug-07-18 06:00PM  Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:57PM  Protagonist Therapeutics: 2Q Earnings Snapshot Associated Press
04:01PM  Protagonist Therapeutics Reports Second Quarter 2018 Financial Results PR Newswire
08:00AM  Todays Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
Aug-06-18 07:01AM  Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis PR Newswire +58.63%
07:00AM  Protagonist Therapeutics Secures $22 Million Equity Financing PR Newswire
Aug-01-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Protagonist Therapeutics, HD Supply, BIOHAVEN PHARM, Big Lots, Clean Energy Fuels, and H&E Equipment Services New Research Emphasizes Economic Growth GlobeNewswire
Jun-18-18 07:00AM  Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting PR Newswire
Jun-06-18 07:00AM  Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference PR Newswire
Jun-01-18 07:00AM  Protagonist Therapeutics Reports Granting of Inducement Award PR Newswire
May-24-18 04:30PM  Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer PR Newswire
May-22-18 07:30AM  Report: Developing Opportunities within Integer, Sykes Enterprises, Protagonist Therapeutics, Egalet, Watsco, and Extra Space Storage Future Expectations, Projections Moving into 2018 GlobeNewswire
May-17-18 10:14AM  Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association PR Newswire -7.13%
May-16-18 08:00AM  Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors PR Newswire
May-09-18 05:16PM  Protagonist Therapeutics: 1Q Earnings Snapshot Associated Press
04:02PM  Protagonist Therapeutics Reports First Quarter 2018 Financial Results PR Newswire
May-03-18 08:00AM  Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference PR Newswire
Apr-13-18 08:18AM  Protagonist Therapeutics (PTGX) Enters Oversold Territory Zacks
Mar-28-18 05:02PM  Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion Zacks -6.31%
08:25AM  Recent Analysis Shows ICU Medical, Motorcar Parts of America, Protagonist Therapeutics, A. Schulman, PennantPark Investment, and H&E Equipment Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-27-18 10:08AM  Protagonist Therapeutics Stalls Ulcerative Colitis Study Zacks
Mar-26-18 04:31PM  Why KB Home, Longfin, and Protagonist Therapeutics Slumped Today Motley Fool -57.17%
11:45AM  Why Protagonist Therapeutics, Inc. Is Imploding Today Motley Fool
06:45AM  Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis PR Newswire
Mar-09-18 08:00AM  Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference PR Newswire +14.09%
Mar-08-18 06:26PM  Edited Transcript of PTGX earnings conference call or presentation 7-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-07-18 04:58PM  Protagonist Therapeutics posts 4Q loss Associated Press
04:02PM  Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results PR Newswire
12:00PM  Protagonist Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
06:43AM  Analysts Expect Breakeven On The Horizon For Protagonist Therapeutics Inc (NASDAQ:PTGX) Simply Wall St.
Mar-06-18 04:30PM  FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia PR Newswire
Mar-01-18 04:00PM  Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference PR Newswire
07:00AM  Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow PR Newswire
Jan-31-18 08:00AM  Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-29-18 12:14PM  Protagonist Therapeutics 'Poised For Upside,' Stifel Says Benzinga +13.10%
Jan-25-18 07:40AM  Analysis: Positioning to Benefit within AllianceBernstein Holding, Motorcar Parts of America, Aegion, Zix, Workiva, and Protagonist Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jan-04-18 08:00AM  Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 PR Newswire
Dec-15-17 09:12AM  The Zacks Analyst Blog Highlights: Halozyme Therapeutics, Protagonist Therapeutics, Aptose Biosciences and Pieris Pharmaceuticals Zacks
Dec-14-17 06:31AM  Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors PR Newswire
06:30AM  Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 PR Newswire
Dec-04-17 08:00AM  Protagonist Therapeutics to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference PR Newswire -8.21%
Nov-20-17 07:25AM  Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 20, 2017 Capital Cube +6.67%
Nov-10-17 01:24PM  Protagonist Therapeutics, Inc. Value Analysis (NASDAQ:PTGX) : November 10, 2017 Capital Cube
Nov-09-17 08:00AM  Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200 PR Newswire
07:19AM  Protagonist Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTGX-US : November 9, 2017 Capital Cube
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Liu David YChief Scientific OfficerAug 06Sale8.853,39530,04449,802Aug 08 06:17 PM
PATEL DINESH V PH DPresident and CEOAug 06Sale8.8510,79295,535374,792Aug 08 06:15 PM
SELICK HAROLD EDirectorApr 01Option Exercise1.313,3104,3363,310Apr 02 07:19 PM
Liu David YChief Scientific OfficerMar 01Sale8.038106,50451,197Mar 04 06:35 PM
PATEL DINESH V PH DPresident and CEOMar 01Sale8.032,18317,529383,831Mar 04 06:33 PM
Shames Richard S.Chief Medical OfficerMar 01Sale8.036575,27632,021Mar 04 06:29 PM
PATEL DINESH V PH DPresident and CEOFeb 06Sale7.7410,90984,410357,264Feb 08 05:37 PM
Liu David YChief Scientific OfficerFeb 06Sale7.743,82129,56237,007Feb 08 05:30 PM
Shames Richard S.Chief Medical OfficerFeb 06Sale7.742,77821,50624,178Feb 08 05:27 PM
PATEL DINESH V PH DPresident and CEOJan 11Option Exercise1.1622,34425,919368,173Jan 14 07:00 PM